YYLSG
2021-11-24
Like
Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook 通过以 20% 折扣发行的股票筹集 5000 万美元后股价暴跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
12
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":874669498,"tweetId":"874669498","gmtCreate":1637767023325,"gmtModify":1637767023418,"author":{"id":3585128891404621,"idStr":"3585128891404621","authorId":3585128891404621,"authorIdStr":"3585128891404621","name":"YYLSG","avatar":"https://static.tigerbbs.com/41bee2bd52d9d3dc3a494bc99d85290d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874669498","repostId":1182883462,"repostType":4,"repost":{"id":"1182883462","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637765117,"share":"https://www.laohunote.com/m/news/1182883462?lang=zh_CN&edition=full","pubTime":"2021-11-24 22:45","market":"us","language":"en","title":"Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook 通过以 20% 折扣发行的股票筹集 5000 万美元后股价暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182883462","media":"Benzinga Earnings","summary":"Outlook shares plunged more than 22% in early trading.Outlook Therapeutics Inc has increased the siz","content":"<p>Outlook shares plunged more than 22% in early trading.<img src=\"https://static.tigerbbs.com/400d88d0cf7a467f2553f97a56faba44\" tg-width=\"868\" tg-height=\"610\" referrerpolicy=\"no-referrer\"><b>Outlook Therapeutics Inc</b> has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.</p><p><blockquote>Outlook 股价早盘暴跌超过 22%。<b>展望治疗公司</b>将之前宣布的公开发行规模增加到 4000 万股，每股价格为 1.25 美元，总收益为 5000 万美元。报价较周二最后收盘价 1.56 美元折扣近 20%。</blockquote></p><p> Previously, the Company offered 8 million shares at $1.25 per share.</p><p><blockquote>此前，该公司以每股1.25美元的价格发行了800万股股票。</blockquote></p><p> The offering will close by November 29.</p><p><blockquote>发行将于 11 月 29 日截止。</blockquote></p><p> H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.</p><p><blockquote>H.CWainwright & Co. 担任此次发行的唯一账簿管理人。</blockquote></p><p> GMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.</p><p><blockquote>GMS Ventures and Investments 是 Outlook Therapeutics 最大股东和战略合作伙伴 BioLexis Pte 的附属公司。有限公司表示有兴趣直接或通过关联公司购买最多 2000 万美元的发行股份。</blockquote></p><p> Outlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.</p><p><blockquote>Outlook Therapeutics 将把净收益用于营运资金和一般企业用途，包括支持其 ONS-5010 开发计划。</blockquote></p><p> Recently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.</p><p><blockquote>最近，Outlook在AAO 2021年视网膜亚专业日年会上展示了ONS-5010的3期NORSE TWO试验的关键安全性和有效性数据。</blockquote></p><p> ONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,</p><p><blockquote>ONS-5010是贝伐珠单抗的研究性眼科制剂，用于湿性年龄相关性黄斑变性（湿性AMD）和其他视网膜适应症，</blockquote></p><p> Outlook Therapeutics plans to submit a marketing application in Q1 of 2022.</p><p><blockquote>Outlook Therapeutics 计划于 2022 年第一季度提交营销申请。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook 通过以 20% 折扣发行的股票筹集 5000 万美元后股价暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook 通过以 20% 折扣发行的股票筹集 5000 万美元后股价暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-11-24 22:45</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Outlook shares plunged more than 22% in early trading.<img src=\"https://static.tigerbbs.com/400d88d0cf7a467f2553f97a56faba44\" tg-width=\"868\" tg-height=\"610\" referrerpolicy=\"no-referrer\"><b>Outlook Therapeutics Inc</b> has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.</p><p><blockquote>Outlook 股价早盘暴跌超过 22%。<b>展望治疗公司</b>将之前宣布的公开发行规模增加到 4000 万股，每股价格为 1.25 美元，总收益为 5000 万美元。报价较周二最后收盘价 1.56 美元折扣近 20%。</blockquote></p><p> Previously, the Company offered 8 million shares at $1.25 per share.</p><p><blockquote>此前，该公司以每股1.25美元的价格发行了800万股股票。</blockquote></p><p> The offering will close by November 29.</p><p><blockquote>发行将于 11 月 29 日截止。</blockquote></p><p> H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.</p><p><blockquote>H.CWainwright & Co. 担任此次发行的唯一账簿管理人。</blockquote></p><p> GMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.</p><p><blockquote>GMS Ventures and Investments 是 Outlook Therapeutics 最大股东和战略合作伙伴 BioLexis Pte 的附属公司。有限公司表示有兴趣直接或通过关联公司购买最多 2000 万美元的发行股份。</blockquote></p><p> Outlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.</p><p><blockquote>Outlook Therapeutics 将把净收益用于营运资金和一般企业用途，包括支持其 ONS-5010 开发计划。</blockquote></p><p> Recently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.</p><p><blockquote>最近，Outlook在AAO 2021年视网膜亚专业日年会上展示了ONS-5010的3期NORSE TWO试验的关键安全性和有效性数据。</blockquote></p><p> ONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,</p><p><blockquote>ONS-5010是贝伐珠单抗的研究性眼科制剂，用于湿性年龄相关性黄斑变性（湿性AMD）和其他视网膜适应症，</blockquote></p><p> Outlook Therapeutics plans to submit a marketing application in Q1 of 2022.</p><p><blockquote>Outlook Therapeutics 计划于 2022 年第一季度提交营销申请。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182883462","content_text":"Outlook shares plunged more than 22% in early trading.Outlook Therapeutics Inc has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.\nPreviously, the Company offered 8 million shares at $1.25 per share.\nThe offering will close by November 29.\nH.C. Wainwright & Co. is acting as the sole book-running manager for the offering.\nGMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.\nOutlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.\nRecently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.\nONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,\nOutlook Therapeutics plans to submit a marketing application in Q1 of 2022.","news_type":1,"symbols_score_info":{"OTLK":0.9}},"isVote":1,"tweetType":1,"viewCount":946,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/874669498"}
精彩评论